COPD Expert Opinions

Meet the expert

Ian Pavord

Ian D. Pavord, MA, DM, FRCP, FERS, FMedSci, is Professor of Respiratory Medicine at the University of Oxford and Honorary Consultant Physician at the Oxford University Hospitals. He was an inaugural Fellow of ERS in 2014 and became a Fellow of the Academy of Medical Science in 2015. Prof. Pavord has a research interest in the clinical aspects of inflammatory airway diseases and has pioneered the use of non-invasive measures of airway inflammation. He has identified several clinically important phenotypes of inflammatory airway disease, discovered clinically important biomarkers, and played a lead role in the clinical development of 3 treatments for severe airway disease.

Disclosures:

Professor Pavord has received honoraria for speaking at sponsored meetings from Aerocrine, AstraZeneca, Almirall, Boehringer Inglehiem, Chiesi, GlaxoSmithKline, Novartis, Menarini, Sanofi and Regeneron, and Teva Pharmaceuticals, and payments for organizing educational events from AstraZeneca, GlaxoSmithKline, Sanofi and Regeneron, and Teva Pharmaceuticals. Professor Pavord has received honoraria for attending advisory panels with AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Genentech, GlaxoSmithKline, Knopp, Novartis, Merck, Sanofi and Regeneron, and Teva Pharmaceuticals, and payments to support FDA approval meetings from GlaxoSmithKline. Professor Pavord has received sponsorship to attend international scientific meetings from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Teva Pharmaceuticals. Professor Pavord has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. Professor Pavord is co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Bayer, Insmed, and Merck. In 2014–5 he was an expert witness for a patent dispute involving AstraZeneca and Teva Pharmaceuticals.